STOK News and Press, Stoke Therapeutics Inc. From 10/09/25

– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal change in natural history – – Improvements in overall clinical status...

2025-10-08 15:28:43 ET DENVER, Colo., Oct 08, 2025 ( 247marketnews.com )- Here’s your Power Hour watchlist , full of names with fresh catalysts and eyes on the afterhours tape. VENU (NYSE:VENU) is stealing the spotlight after reporting over $23 million in demand f...

2025-10-06 07:35:14 ET More on Stoke Therapeutics Stoke Therapeutics: Vulnerable To Profit Taking Seeking Alpha’s Quant Rating on Stoke Therapeutics Historical earnings data for Stoke Therapeutics Financial information for Stoke Therapeutics ...

Leader with Long Track Record in Building World-Class Biopharma Companies and Driving Late-Stage Development and Commercial Execution Arthur Tzianabos Resumes Chairman of the Board Role Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring pro...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatmen...

2025-09-15 20:21:09 ET This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F stock portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory 13F Form filed on 08/14/2025. The 13F portfolio value in...

– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies – – Substantial increase in seizure-free days and continuous improvements in qu...

– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies – – Substantial increase in seizure-free days and continuous improvements in qu...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatmen...

2025-08-27 10:06:16 ET Shares of RNA medicine concern Stoke Therapeutics, Inc. ( STOK ) have more than tripled off their recent lows in early April. Stoke's antisense oligonucleotide zorevunersen has demonstrated significant seizure reduction in Dravet syndrome patie...